|Matthew Ringel MD, PhD
Ralph W Kurtz Professor of Medicine, and Director of the Division of Endocrinology and Metabolism at The Ohio State University, OH, USA
Dr Ringel is the Co-Director of the Center for Cancer Engineering and Co-Leader of the Cancer Biology at Ohio State Comprehensive Cancer Center. He also serves as the Deputy Director of the OSU Center for Clinical and Translational Sciences. Dr Ringel’s NIH-funded laboratory is interested in defining the signaling pathways that regulate thyroid cancer progression and therapeutic resistance. His group’s work has focused on PI3 kinase/AKT and PAK signaling, metastasis-suppressing pathways, and transcriptional regulation of oncogenes in thyroid and other cancer types. He has an active clinical practice focused on thyroid cancer. He has been a member of the thyroid cancer NCCN guidelines committee, the National Cancer Institute Head and Neck Steering Committee, and currently is the co-Chair of the American Thyroid Association Thyroid Cancer Guidelines task force. To find out more about Professor Ringel and his vision for the journal please see here.
|Márta Korbonits MD, PhD
Professor of Endocrinology and Metabolism, William Harvey Research Institute at Barts and the London School of Medicine, Queen Mary University of London, UK
Márta Korbonits is a clinical academic endocrinologist. She works on the clinical characterisation as well as molecular aspects of pituitary diseases and has special interest in endocrine tumour-related genetics. She also studied hormonal-related metabolic alterations. She was founding Associate Editor for the pituitary field of the Journal of the Endocrine Society before joining Endocrine-Related Cancer.
|Emily K Bergsland MD
Professor of Clinical Medicine, University of California, San Francisco, USA
Professor Bergsland is a Professor of Medicine and Associate Director for Education (Helen Diller Family Comprehensive Cancer Center) at the University of California, San Francisco (UCSF). She is the director of the UCSF Center for Neuroendocrine Tumors and her research focuses on the development and testing of novel therapies for neuroendocrine tumors (NETs). Dr Bergsland has held a number of NET-related national leadership positions, including serving as president of the Board of Directors for the North American Neuroendocrine Tumor Society (NANETS).
|Lois Mulligan PhD
Professor, Cancer Research Institute at Queen’s University, Kingston, Canada
Professor Mulligan's research focuses broadly on regulation of cellular processes that contribute to neuroendocrine tumour growth and spread. Primary interests include intracellular protein localization and trafficking, mechanisms of cell motility and invasive spread, and regulation of receptor signalling in neuroendocrine cell models.
|Hironobu Sasano MD, PhD
Professor and Chairman, Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
Professor Sasano is one of the leaders in the fields of endocrine action and metabolism in breast cancer, working particularly on the intracrine actions of both estrogens and androgens. He has contributed significantly to the recognition of the clinical importance of intratumoral estrogen production. He is the President of the Japanese Hormone and Cancer Society, and serves on the annual steering committee of The Endocrine Society and the WHO Endocrine Tumor Fascicle panel.
|Martin Schlumberger MD, PhD
Emeritus Professor of Oncology at University Paris-Saclay, Paris, France
Martin Schlumberger is Emeritus Professor of Oncology at University Paris-Saclay. He chaired the Department of Nuclear Medicine and Endocrine Oncology at Gustave Roussy, Villejuif. He focused for 40 years on endocrine tumors, mostly thyroid cancers and on the use of radioisotopes for therapy. He was principal investigator of 18 trials in refractory thyroid tumors that led to the label of four Tyrosine Kinase Inhibitors and of prospective studies in low risk cancers to avoid overtreatment. He has published 390 original papers in English-language peer-reviewed journals.
|Wayne Tilley PhD
Director, Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, SA, Australia
Professor Tilley is a cancer biologist and international expert in androgen receptor (AR) function in breast and prostate cancer. His laboratory has contributed to understanding the molecular mechanisms of resistance to hormonal therapies used in the treatment of prostate cancer. A current major research focus is the development of new treatments for prostate cancer that target the AR. His expertise spans the areas of steroid receptor structure and function, animal models of cancer, biomarkers, molecular biology, therapeutics and human explant cultures.
|John Wass MD, PhD
Professor of Endocrinology, University of Oxford and Churchill Hospital, Oxford, UK
Professor Wass is professor of endocrinology at the University of Oxford and works at the Churchill Hospital in Oxford, where he is a clinical academic endocrinologist working on pituitary tumours, Addison's disease, osteoporosis and obesity. Professor Wass is currently engaged in a number of research projects including somatostatin responsive headaches in acromegaly, disparate growth hormone and IGF-I values in acromegaly on treatment and a paper on giants with Professor Korbonits.
|R Clarke PhD, DSc
The Hormel Institute, University of Minnesota, MN, USA
Robert Clarke, PhD, DSc, is an internationally recognized leader in breast cancer research. Dr Clarke’s research applies cellular, molecular and computational methods to data from ongoing translational studies in both humans and experimental models to explore the mechanisms driving resistance to antihormone and cytotoxic therapies in breast cancer. He has developed a series of hormone resistant breast cancer models that are now widely used in the field. Dr Clarke and his colleagues have begun to identify components of the molecular signaling network that integrates cell stress signaling, protein misfolding, and communication among the endoplasmic reticulum, mitochondria and nucleus of breast cancer cells. Ultimately, this network determines if a breast cancer cell will proliferate, differentiate or die, and the mechanism by which the cell will die (apoptosis, autophagy, necrosis, senescence), in response to therapy. Dr Clarke serves on the editorial boards of several respected cancer journals. He has also served as chair of two NIH peer-review study sections (Basic Mechanisms of Cancer Therapeutics; National Center for Complementary and Alternative Medicine – Basic Science) and chaired multiple other peer-review panels. Dr Clarke is an elected Fellow of the Royal Society of Chemistry, a Fellow of the Royal Society of Medicine, and a Fellow of the Society of Biology in the UK.
|A Di Cristofano PhD
Professor of Developmental and Molecular Biology, Albert Einstein College of Medicine, New York, NY, USA
Professor Di Cristofano's general area of expertise is cancer biology and signaling. His work has made seminal contributions to the elucidation of the key role played by the PI3K signaling cascade in the pathogenesis of follicular and anaplastic thyroid cancer. His current research is focused on the identification of the genetic, metabolic, and signaling changes associated in vivo with thyroid cancer progression and resistance to therapy using sophisticated genetically modified mouse models.
|J Favier PhD
Research Professor, Head of the Genetics and Metabolism of Rare Cancers Laboratory, INSERM U970 – Paris-Cardiovascular Research Centre of the Georges Pompidou Hospital (HEGP), Université de Paris, Paris, France
Dr Favier’s primary interests are the fields of pheochromocytomas and paragangliomas and familial cancers associated with mitochondrial dysfunctions. She has a strong interest in mutations in genes encoding TCA cycle enzymes such as succinate dehydrogenase (SDH). Thanks to the wide collection of tumours of the COMETE network and to the unique experimental models generated in the lab, she has made pioneering discoveries in the field, demonstrating the links between SDH mutations and pseudo-hypoxia, epithelial-to-mesenchymal transition or epigenetic modifications. Dr Favier was the previous co-chair of the Pheochromocytoma Research Support Organization (PRESSOR) and is the current head of the pheochromocytoma and paraganglioma working group of the European Network for the Study on Adrenal Tumors (ENS@T).
|P Ghosh PhD
Associate Professor of Biochemistry and Molecular Medicine in the University of California Davis (UCD), CA, USA, with joint appointments in the Department of Urology, UCD, and the VA Northern California Health Care System
Paramita M Ghosh, PhD's expertise lies in the study of signal transduction pathways, especially related to prostate cancer. Dr Ghosh is a chartered member of the Basic Mechanisms in Cancer Therapeutics Study Section of the National Institutes of Health, and has also been a repeat reviewer for the Department of Defense Congressionally Directed Medical Research Programs. She is a member of the American Association for Cancer Research and her work has been awarded both at home and abroad.
|W W de Herder MD, PhD
Professor of Endocrine Oncology, Erasmus MC, Rotterdam, Netherlands
Professor de Herder’s major research interests are neuroendocrine and adrenal tumors/Cushing’s syndrome and history of (neuro-)endocrinology. He is a member of several international and Dutch national societies. He served as chairman and vice-chairman of ENETS as well as advisor of ENETS and North American Neuroendocrine Tumor Society (NANETS).
|D J Marsh PhD
Professor, Medical Science, and Head, Translational Oncology Group, University of Technology Sydney, Sydney, Australia
Professor Marsh’s primary interests are in the fields of Familial cancer and ovarian cancer. She has a strong interest in the genetics of endocrine disorders, most recently studying the tumour suppressor CDC73/HRPT2 shown to be a member of the human PAF1 complex with key transcriptional roles. Her work in ovarian cancer has included investigation of the role of hormonal influences, histone modifications and key pathways contributing to this malignancy.
|C J McCabe BSc, PhD
Professor of Molecular Endocrinology, Deputy Director of the Institute of Metabolism and Systems Research, Theme Lead for Endocrinology, University of Birmingham, UK
Professor Chris McCabe’s research group focuses on proto-oncogenes in thyroid and breast cancers, mechanisms of aneuploidy and genetic instability, and the action of the sodium iodide symporter NIS in thyroid and breast tumours. The McCabe group currently holds funding from numerous funders including the Medical Research Council, NIHR and the Department of Defence. Chris was until 2019 Chair of the Wellcome Trust Basic Science Interview Committee (BSIC), and is currently a member of multiple national and international committees including the International Congress for Endocrinology POC and the Science Committee of the European Society of Endocrinology. He currently chairs the American Thyroid Association POC.
|J Ngeow MBBS, FRCP, MPH
Associate Professor, Genomic Medicine, Lee Kong Chian School of Medicine, Nanyang Technological University, and Senior Consultant, Division of Medical Oncology at the National Cancer Centre, Singapore
Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic interest in hereditary cancer syndromes and translational clinical cancer genetics. Dr Ngeow is funded by the National Medical Research Council and Ministry of Health Singapore to explore how gene-environmental interactions predisposes to cancer initiation and progression and the implementation of genomics into routine clinical care in Asia. She has active studies understanding the genetic basis of thyroid, breast and endometrial cancers, as well as soft tissue sarcomas.
|C Stratakis D(Med)Sc, MD
Chief Scientific Officer, ELPEN, Athens, Greece
Professor Stratakis currently leads a research program on Human Genetics & Precision Medicine at the Foundation for Research & Technology (FORTH) while serving as the Chief Scientific Officer of ELPEN Inc. and retaining visiting or adjunct professorships in academic centres internationally. Professor Stratakis is the founding Director of a new Research Institute dedicated to genetics and personalized medicine in Athens, Greece, that is expected to open in 2023/24. His award-winning research focused on genetics, and he has identified genes involved in a number of human diseases and tumor formation. He is the author of more than 800 publications, and has received multiple awards and honors including the Society for Endocrinology’s Dale Medal in 2019. He holds four patents and has been named Professor at universities internationally.
|F Weber MD
Professor of Surgery, University Hospital Essen, Department of General-, Visceral- and Transplantation Surgery, Essen, Germany
Professor Weber is responsible for the endocrine surgical program at the University Hospital Essen. His areas of expertise are endocrine oncology and endocrine tumor genetics. His primary areas of research are endocrine neoplasia and human cancer genetics. In addition, his research focuses on the elucidation of tumor-stroma interaction in visceral neoplasia.
|EARLY CAREER EDITORS|
|J H Ho, MBChB PhD
Consultant Endocrinologist, The Christie NHS Foundation Trust, Manchester, UK
Dr Ho is a clinical endocrinologist and maintains an active clinical research portfolio. He undertook his PhD at the University of Manchester, studying novel cardiovascular risk markers in obesity and metabolic conditions. His research interest is in cardiovascular complications and outcomes in endocrine conditions, with a focus on improving clinical practice through the utility of large clinical datasets.
|T Vandamme, MD PhD
Consultant in digestive and neuroendocrine oncology, NETwerk, University Hospital Antwerp, Edegem, Belgium
Dr Vandamme’s primary research interests are neuroendocrine cancer genomics and drug resistance mechanisms. His most recent work as a postdoctoral fellow at the Center for Oncological Research (CORE), University of Antwerp, focuses on the role of circulating tumor DNA as a neuroendocrine neoplasm biomarker and development of patient-derived neuroendocrine cancer organoids. Currently, he serves as a Coordinator of NETwerk, the first European Neuroendocrine Tumor Society (ENETS) Network of Excellence in Antwerp, Belgium. In addition, he is secretary of the Dutch–Belgian Neuroendocrine Tumor Society (DBNETS), member of the ENETS NextGen group and member of the Belgian Group of Digestive Oncology (BGDO) NET steering committee.
University of Birmingham, UK
Dr Sarah Berhane is a research fellow in medical statistics working in the Institute of Applied Health Research at the University of Birmingham. Her main research interests are diagnostic and prognostic modelling for the purpose of clinical prediction. She also works on projects related to systematic reviews of diagnostic test accuracy.
Ohio State University, USA
Dr Brock is an Associate Professor in the Department of Biomedical Informatics, The Ohio State University College of Medicine (OSU-COM). He serves as Associate Director of the Center for Biostatistics, Director of the Biostatistics Resource at Nationwide Children’s Hospital (BRANCH), and Director of the Biostatistics, Epidemiology, and Research Design (BERD) Core of the Center for Clinical Translational Science (CCTS). He currently serves as the lead biostatistician on multiple ongoing clinical trials, ranging from early phase studies to community-based pragmatic interventions incorporating both efficacy and implementation outcomes.
|M J Campbell
Ohio State University, USA
Professor Campbell is a Professor of Oncology at The Ohio State University. His research aims to understand how disruptions to the epigenome can act as disease-drivers in hormone responsive cancers, with the goal to exploit this understanding in either diagnostic or therapeutic settings. In 2010, Professor Campbell completed a masters in Bioinformatics at Johns Hopkins University, and since then has developed strong expertise in the analyses and integration of genomic and epigenomic data sets, and their integration with publicly available data to annotate experimental findings. Specifically, his research leverages ChIP-Seq, RNA-Seq (including splice aware), proteomics such as RIME, and other NGS approaches to study non-coding: coding RNA interactions and RNA modifications.
N Bhowmick, USA
F Cetani, Italy
F Claessens, Belgium
A Daly, Belgium
S Das, USA
S Dehm, USA
T Else, USA
A Gill, Australia
O Gimm, Sweden
C Heaphy, USA
H Heemers, USA
R Hicks, Australia
G Kaltsas, Greece
J Knauf, USA
A Lam, Australia
R Leung, USA
L B Mercado, Philippines
N Mitsiades, Czech Republic
L Murphy, Canada
F Nabhan, USA
N Nakagawa, Japan
F Pitoia, Argentina
Y Rhee, Republic of Korea
P W Rosario, Brazil
P Santisteban, Spain
M Sarquis, Brazil
L Selth, Australia
S Uchino, Japan
M Xing, USA
M Zatelli, Italy
A Zoubeidi, Canada
W Zwart, Netherlands